ArticleDiscover oncology2025
Evaluation of serum MUC5AC for identifying high grade cervical lesions in a prospective cohort from Türkiye.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbnormal expression of mucins and changes in their glycosylation are linked to the onset and advancement of cancerous conditions. This research sought to assess the diagnostic significance of serum MUC5AC levels in differentiating between high-grade cervical intraepithelial lesions, low-grade lesions, and normal cervical findings, as well as to investigate its potential as a non-invasive biomarker to enhance cervical cancer screening and early detection methods.
methodsA total of 138 women were stratified into three groups: CIN 1 (LSIL) (n = 38), CIN 2-3 (HSIL) (n = 54), and controls (n = 46). Serum levels of MUC5AC were assessed through enzyme-linked immunosorbent assay (ELISA). All participants underwent cytological assessment, HPV testing, and colposcopy with targeted biopsy; endocervical curettage and LEEP were performed when indicated.
resultsSerum MUC5AC levels were significantly higher in the CIN 2-3 group compared to both the control and CIN 1 groups (p = 0.016), while no significant difference was found between the control and CIN 1 groups. ROC analysis demonstrated that MUC5AC had moderate diagnostic performance in distinguishing CIN 2-3 from controls (AUC = 0.634, p = 0.022) and from CIN 1 (AUC = 0.658, p = 0.011), with high sensitivity but low specificity. No significant discriminative value was observed in the comparisons involving the CIN 1 and control groups.
conclusionSerum MUC5AC exhibited significant sensitivity in detecting high-grade cervical lesions; however, its specificity was somewhat restricted. Although it may not serve as an adequate standalone marker for early lesions, it shows potential for identifying advanced pathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.